Chemotherapy-Induced Peripheral Neuropathy Market Expected to grow due to increased spending on R&D as well as the introduction of novel therapies

Chemotherapy-Induced Peripheral Neuropathy Market

DelveInsight’s Chemotherapy-Induced Peripheral Neuropathy market report covers historical and predicted epidemiology, as well as Chemotherapy-Induced Peripheral Neuropathy market trends in the 7MM (the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also covers current Chemotherapy-Induced Peripheral Neuropathy treatment methods/algorithms, Chemotherapy-Induced Peripheral Neuropathy market drivers, Chemotherapy-Induced Peripheral Neuropathy, and unmet medical needs.

Some of the Important Findings from the Chemotherapy-Induced Peripheral Neuropathy Market Report

• As per DelveInsight’s Chemotherapy-Induced Peripheral Neuropathy epidemiology insights, the incident population was estimated to be more than 590,000 out of which the moderate cases were higher than mild and severe CIPN in the United States in 2017. 

• Japan accounted for approximately 18.11% of the total CIPN incident cases in the 7MM in 2017.

• Among the EU5 countries, Germany had the highest CIPN incident cases while Spain had the lowest CIPN incident population in 2017.

• The major key players including Solasia, WEX Pharmaceuticals, ESTEVE (E-52862), and others hold the potential to create a significant positive shift in CIPN market size. 

• E-52862 (MR309) developed by ESTEVE is a selective 1R antagonist that has recently completed Phase II clinical trials for neuropathic pain and could be a first-in-class analgesic. 

• SP-04, developed by Pledpharma and acquired by Solasia, is a first-in-class drug candidate designed to protect patients with adjuvant or metastatic colorectal cancer from the nerve damage that can occur during chemotherapy treatment.

Want to learn more? Request sample @ Chemotherapy-Induced Peripheral Neuropathy Treatment Guidelines

The Chemotherapy-Induced Peripheral Neuropathy market report covers current treatment practices, emerging drugs, Chemotherapy-Induced Peripheral Neuropathy market share of individual therapies, and current and forecasted Chemotherapy-Induced Peripheral Neuropathy market size from 2017 to 2030, segmented by seven major markets.

Chemotherapy-Induced Peripheral Neuropathy: Overview

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-dependent side effect of anticancer drugs such as platinums, taxanes, epothilones, vinca alkaloids, and newer agents like bortezomib. It not only causes dose reductions or treatment discontinuation, but it also lowers the quality of life of cancer survivors. CIPN occurs in 20% of patients receiving standard chemotherapy doses and in nearly 100% of patients receiving high doses.

Chemotherapy-Induced Peripheral Neuropathy Epidemiology Segmentation

The Chemotherapy-Induced Peripheral Neuropathy report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

• Chemotherapy-Induced Peripheral Neuropathy Total Incident Cases 

• Chemotherapy-Induced Peripheral Neuropathy Severity-Specific Incident Population

• Chemotherapy-Induced Peripheral Neuropathy Incident Population by Chemotherapeutic Agents 

• Chemotherapy-Induced Peripheral Neuropathy Incident Population by Cancer Type

Chemotherapy-Induced Peripheral Neuropathy Treatment Landscape

Due to the lack of approved targeted therapies, the current CIPN therapeutic landscape in the 7MM is dominated by off-label therapies. Major Off-label therapies used to treat CIPN symptoms include alpha-2-delta antagonists (anticonvulsants), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics.

Chemotherapy-Induced Peripheral Neuropathy Market 

The launch of therapies such as SP-04, Halneuron, E-52862, and others by key pharmaceutical companies such as Solasia, WEX Pharmaceuticals, ESTEVE, and several others is anticipated to provide a major push to the growth of the CIPN market size in the forecast period 2020-30 in the 7MM. 

Find out which player or emerging drug is going to get the maximum share @ Chemotherapy-Induced Peripheral Neuropathy Market Size

Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapies and Key Players 

• SP-04: Solasia

• Halneuron: WEX Pharmaceuticals

• E-52862: ESTEVE

Chemotherapy-Induced Peripheral Neuropathy Market Drivers

• Increasing CIPN emerging therapies

• Increasing awareness

Chemotherapy-Induced Peripheral Neuropathy Market Barriers

• No standard assessment

• Current therapy limitations

• Herbal remedies

• Clinical understanding

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2017-30

CIPN Key Companies: Solasia, WEX Pharmaceuticals, ESTEVE, among others. 

CIPN Key Pipeline Therapies: SP-04, Halneuron, E-52862,and others.

CIPN Segmentation: By Geography, By CIPN therapies

Analysis: Comparative and conjoint analysis of CIPN  emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Chemotherapy Induced Neutropenia Market

Get comprehensive historical and forecast analysis of Chemotherapy Induced Neutropenia Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Amgen, G1 Therapeutics, Evive Biotech, Myelo Therapeutics, Cellerant Therapeutics, Aileron Therapeutics, Spectrum Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/